Deuterx, LLC
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds (US 9,090,585) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for 3-(SUBSTITUTED-4-Oxoquinazolin-3(4H)-YL)-3-Deutero-PIPERIDINE-2,6-Dione Derivatives and Compositions Comprising and Methods of Using the Same (US 10,555,946) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 2 fees due Sep 3 to 22, 2027 · next Sep 3
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,576,071 | Deuterium-enriched pioglitazone In force · From the USPTO record | In force | From the USPTO record | |
| US 10,940,143 | Deuterium-enriched pioglitazone In force · From the USPTO record | In force | From the USPTO record | |
| US 9,090,585 | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,290,475 | 3-(SUBSTITUTED-4-Oxoquinazolin-3(4H)-YL)-3-Deutero-PIPERIDINE-2,6-Dione Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 9,913,845 | 3-(SUBSTITUTED-4-Oxoquinazolin-3(4H)-YL)-3-Deutero-PIPERIDINE-2,6-Dione Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 10,555,946 | 3-(SUBSTITUTED-4-Oxoquinazolin-3(4H)-YL)-3-Deutero-PIPERIDINE-2,6-Dione Derivatives and Compositions Comprising and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,491,156 | 3-(SUBSTITUTED-4-Oxoquinazolin-3(4H)-YL)-3-Deutero-PIPERIDINE-2,6-Dione Derivatives and Compositions Comprising and Methods of Using the Same In force · Medium confidence | In force | Medium confidence | |
| US 11,141,411 | Methods of Treating Neurological, Metabolic, and Other Disorders Using Enantiopure Deuterium-Enriched Pioglitazone In force · High confidence | In force | High confidence | |
| US 9,809,603 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,189,858 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 11: 19 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 6 abandoned · 11 no status recorded